Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Common Equity (2019 - 2025)

Historic Common Equity for Strata Critical Medical (SRTAW) over the last 7 years, with Q3 2025 value amounting to $283.0 million.

  • Strata Critical Medical's Common Equity rose 2119.97% to $283.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $283.0 million, marking a year-over-year increase of 2119.97%. This contributed to the annual value of $221.9 million for FY2024, which is 527.61% down from last year.
  • As of Q3 2025, Strata Critical Medical's Common Equity stood at $283.0 million, which was up 2119.97% from $223.1 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Common Equity registered a high of $296.7 million during Q2 2021, and its lowest value of $7.7 million during Q1 2021.
  • Its 5-year average for Common Equity is $247.0 million, with a median of $262.9 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 572740.83% in 2021, then tumbled by 1464.14% in 2023.
  • Strata Critical Medical's Common Equity (Quarter) stood at $291.4 million in 2021, then fell by 5.79% to $274.5 million in 2022, then dropped by 14.64% to $234.3 million in 2023, then fell by 5.28% to $221.9 million in 2024, then grew by 27.51% to $283.0 million in 2025.
  • Its Common Equity stands at $283.0 million for Q3 2025, versus $223.1 million for Q2 2025 and $219.7 million for Q1 2025.